Oxford Biomedica plc
OXB.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £73,223 | £77,991 | £50,806 | £46,478 |
| % Growth | -6.1% | 53.5% | 9.3% | – |
| Cost of Goods Sold | £41,566 | £43,272 | £32,851 | £28,690 |
| Gross Profit | £31,657 | £34,719 | £17,955 | £17,788 |
| % Margin | 43.2% | 44.5% | 35.3% | 38.3% |
| R&D Expenses | £35,215 | £28,802 | £15,764 | £27,936 |
| G&A Expenses | £0 | £15,347 | £12,573 | £12,575 |
| SG&A Expenses | £20,638 | £15,347 | £12,573 | £12,575 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | -£1,946 | £21,856 | £110,703 |
| Operating Expenses | £55,853 | £42,203 | £50,193 | £151,214 |
| Operating Income | -£24,196 | -£9,430 | -£32,238 | -£131,544 |
| % Margin | -33% | -12.1% | -63.5% | -283% |
| Other Income/Exp. Net | -£1,834 | -£2,099 | -£3,498 | -£4,639 |
| Pre-Tax Income | -£26,030 | -£11,529 | -£35,736 | -£136,183 |
| Tax Expense | £847 | £681 | £663 | -£4,682 |
| Net Income | -£26,360 | -£10,705 | -£32,485 | -£109,534 |
| % Margin | -36% | -13.7% | -63.9% | -235.7% |
| EPS | -0.25 | -0.1 | -0.31 | -1.13 |
| % Growth | -150% | 67.7% | 72.6% | – |
| EPS Diluted | -0.25 | -0.1 | -0.31 | -1.13 |
| Weighted Avg Shares Out | 106,023 | 105,961 | 105,194 | 96,590 |
| Weighted Avg Shares Out Dil | 106,023 | 105,961 | 105,194 | 96,589 |
| Supplemental Information | – | – | – | – |
| Interest Income | £1,076 | £1,477 | £1,759 | £2,693 |
| Interest Expense | £6,759 | £5,259 | £4,580 | £3,550 |
| Depreciation & Amortization | £13,176 | £11,292 | £11,482 | £13,875 |
| EBITDA | -£6,095 | £5,020 | -£19,674 | -£112,225 |
| % Margin | -8.3% | 6.4% | -38.7% | -241.5% |